Literature DB >> 21983936

A nuclear grading system is a strong predictor of survival in epitheloid diffuse malignant pleural mesothelioma.

Kyuichi Kadota1, Kei Suzuki, Christos Colovos, Camelia S Sima, Valerie W Rusch, William D Travis, Prasad S Adusumilli.   

Abstract

Epithelioid mesothelioma is the most prevalent subtype of diffuse malignant pleural mesothelioma in which only staging is prognostic for survival. In this study of epithelioid diffuse malignant pleural mesothelioma, we investigate the prognostic utility of nuclear features. The slides of 232 epithelioid diffuse malignant pleural mesothelioma patients (14 stage I, 54 stage II, 130 stage III, and 34 stage IV) from a single institution were reviewed for the following seven nuclear features: nuclear atypia, nuclear/cytoplasmic ratio, chromatin pattern, intranuclear inclusions, prominence of nucleoli, mitotic count, and atypical mitoses. MIB-1 immunohistochemistry was performed using tissue microarray, and MIB-1 labeling index was recorded as the percentage of positive tumor cells. Median overall survival of all patients was 16 months and correlated with nuclear atypia (P<0.001), chromatin pattern (P=0.031), prominence of nucleoli (P<0.001), mitotic count (P<0.001), and atypical mitoses (P<0.001) by univariate analysis. Multivariate analysis revealed nuclear atypia (P=0.012) and mitotic count (P<0.001) as independent prognostic factors, and these two factors were utilized to create a three-tier nuclear grade score. The resulting nuclear grade stratified patients into three distinct prognostic groups: grade I (n=107, median overall survival=28 months), grade II (n=91, 14 months), and grade III (n=34, 5 months). Not only was nuclear grade an independent predictor of overall survival (P<0.001), but it was also a stronger discriminator of survival than all currently available factors. Furthermore, nuclear grade was associated with time to recurrence (P=0.004) in patients who underwent complete surgical resection (n=159). MIB-1 labeling index correlated with mitotic count (P<0.001) and nuclear atypia (P=0.037) and stratified overall survival (P<0.001) and time to recurrence (P=0.048), confirming the prognostic value of the nuclear grade. Nuclear grading in epithelioid mesothelioma provides a simple, practical, and cost-effective prognostic tool that better stratifies clinical outcome and time to recurrence than currently available clinicopathologic factors.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21983936      PMCID: PMC4080411          DOI: 10.1038/modpathol.2011.146

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  45 in total

1.  Important prognostic factors in patients with malignant pleural mesothelioma, managed surgically.

Authors:  V W Rusch; E S Venkatraman
Journal:  Ann Thorac Surg       Date:  1999-11       Impact factor: 4.330

2.  Prognostic significance of histologic grade and nuclear expression of beta-catenin in synovial sarcoma.

Authors:  T Hasegawa; R Yokoyama; Y Matsuno; T Shimoda; S Hirohashi
Journal:  Hum Pathol       Date:  2001-03       Impact factor: 3.466

3.  Correlation of Ki-67 and p53 with the new World Health Organization/International Society of Urological Pathology Classification System for Urothelial Neoplasia.

Authors:  S J Cina; K J Lancaster-Weiss; K Lecksell; J I Epstein
Journal:  Arch Pathol Lab Med       Date:  2001-05       Impact factor: 5.534

4.  Pleomorphic epithelioid diffuse malignant pleural mesothelioma: a clinicopathological review and conceptual proposal to reclassify as biphasic or sarcomatoid mesothelioma.

Authors:  Kyuichi Kadota; Kei Suzuki; Camelia S Sima; Valerie W Rusch; Prasad S Adusumilli; William D Travis
Journal:  J Thorac Oncol       Date:  2011-05       Impact factor: 15.609

5.  Poor agreement in recognition of abnormal mitoses: requirement for standardized and robust definitions.

Authors:  M Barry; S K Sinha; M B Leader; E W Kay
Journal:  Histopathology       Date:  2001-01       Impact factor: 5.087

6.  Histologic grading of breast cancer: linkage of patient outcome with level of pathologist agreement.

Authors:  L W Dalton; S E Pinder; C E Elston; I O Ellis; D L Page; W D Dupont; R W Blamey
Journal:  Mod Pathol       Date:  2000-07       Impact factor: 7.842

7.  Correlation between nuclear grade and biological prognostic variables in invasive breast cancer.

Authors:  Q Yang; I Mori; T Sakurai; G Yoshimura; T Suzuma; Y Nakamura; M Nakamura; E Taniguchi; T Tamaki; T Umemura; K Kakudo
Journal:  Breast Cancer       Date:  2001       Impact factor: 4.239

8.  Pheochromocytoma of the Adrenal gland Scaled Score (PASS) to separate benign from malignant neoplasms: a clinicopathologic and immunophenotypic study of 100 cases.

Authors:  Lester D R Thompson
Journal:  Am J Surg Pathol       Date:  2002-05       Impact factor: 6.394

Review 9.  Pathogenetic mechanisms of nuclear pleomorphism of tumour cells based on the mutator phenotype theory of carcinogenesis.

Authors:  L P Bignold
Journal:  Histol Histopathol       Date:  2003-04       Impact factor: 2.303

10.  Risk of recurrence in patients with surgically resected stage I non-small cell lung carcinoma: histopathologic and immunohistochemical analysis.

Authors:  Claudia Poleri; José Luis Morero; Beatriz Nieva; María Fernanda Vázquez; Cristina Rodríguez; Ernesto de Titto; Moisés Rosenberg
Journal:  Chest       Date:  2003-06       Impact factor: 9.410

View more
  42 in total

1.  Tumor Budding Correlates With the Protumor Immune Microenvironment and Is an Independent Prognostic Factor for Recurrence of Stage I Lung Adenocarcinoma.

Authors:  Kyuichi Kadota; Yi-Chen Yeh; Jonathan Villena-Vargas; Leonid Cherkassky; Esther N Drill; Camelia S Sima; David R Jones; William D Travis; Prasad S Adusumilli
Journal:  Chest       Date:  2015-09       Impact factor: 9.410

2.  Biomarkers and prognostic factors for mesothelioma.

Authors:  Harvey I Pass
Journal:  Ann Cardiothorac Surg       Date:  2012-11

3.  The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers.

Authors:  Hideki Ujiie; Kyuichi Kadota; Jun-Ichi Nitadori; Joachim G Aerts; Kaitlin M Woo; Camelia S Sima; William D Travis; David R Jones; Lee M Krug; Prasad S Adusumilli
Journal:  Oncoimmunology       Date:  2015-03-19       Impact factor: 8.110

4.  Plasma Biomarker Enrichment of Clinical Prognostic Indices in Malignant Pleural Mesothelioma.

Authors:  Harvey I Pass; Chandra Goparaju; Osvaldo Espin-Garcia; Jessica Donington; Michele Carbone; Devalben Patel; Zhuo Chen; Ronald Feld; John Cho; Shirish Gadgeel; Antoinette Wozniak; Abraham Chachoua; Natasha Leighl; Ming-Sound Tsao; Marc de Perrot; Wei Xu; Geoffrey Liu
Journal:  J Thorac Oncol       Date:  2016-02-21       Impact factor: 15.609

5.  Associations between mutations and histologic patterns of mucin in lung adenocarcinoma: invasive mucinous pattern and extracellular mucin are associated with KRAS mutation.

Authors:  Kyuichi Kadota; Yi-Chen Yeh; Sandra P D'Angelo; Andre L Moreira; Deborah Kuk; Camelia S Sima; Gregory J Riely; Maria E Arcila; Mark G Kris; Valerie W Rusch; Prasad S Adusumilli; William D Travis
Journal:  Am J Surg Pathol       Date:  2014-08       Impact factor: 6.394

6.  Tertiary lymphoid structures in epithelioid malignant peritoneal mesothelioma are associated with neoadjuvant chemotherapy, but not with prognosis.

Authors:  Nazim Benzerdjeb; Peggy Dartigues; Vahan Kepenekian; Séverine Valmary-Degano; Eliane Mery; Gerlinde Avérous; Anne Chevallier; Marie-Hélène Laverriere; Irène Villa; Olivier Harou; Françoise Galateau Sallé; Laurent Villeneuve; Olivier Glehen; Sylvie Isaac; Juliette Hommell-Fontaine; Frédéric Bibeau
Journal:  Virchows Arch       Date:  2021-04-14       Impact factor: 4.064

7.  Malignant peritoneal mesothelioma: prognostic significance of clinical and pathologic parameters and validation of a nuclear-grading system in a multi-institutional series of 225 cases.

Authors:  David B Chapel; Jefree J Schulte; Gudrun Absenger; Richard Attanoos; Luka Brcic; Kelly J Butnor; Lucian Chirieac; Andrew Churg; Françoise Galateau-Sallé; Kenzo Hiroshima; Yin P Hung; Hedy Kindler; Thomas Krausz; Alberto Marchevsky; Mari Mino-Kenudson; Jeffrey Mueller; Kazuki Nabeshima; Kirin Turaga; Ann E Walts; Aliya N Husain
Journal:  Mod Pathol       Date:  2020-10-15       Impact factor: 7.842

8.  Histopathologic features predict survival in diffuse pleural malignant mesothelioma on pleural biopsies.

Authors:  Cyril Habougit; Béatrice Trombert-Paviot; Georgia Karpathiou; François Casteillo; Sophie Bayle-Bleuez; Pierre Fournel; Jean-Michel Vergnon; Olivier Tiffet; Michel Péoc'h; Fabien Forest
Journal:  Virchows Arch       Date:  2017-03-27       Impact factor: 4.064

9.  KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma.

Authors:  Kyuichi Kadota; Camelia S Sima; Maria E Arcila; Cyrus Hedvat; Mark G Kris; David R Jones; Prasad S Adusumilli; William D Travis
Journal:  Am J Surg Pathol       Date:  2016-12       Impact factor: 6.394

10.  New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi-Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center.

Authors:  F Galateau Salle; N Le Stang; A G Nicholson; D Pissaloux; A Churg; S Klebe; V L Roggli; H D Tazelaar; J M Vignaud; R Attanoos; M B Beasley; H Begueret; F Capron; L Chirieac; M C Copin; S Dacic; C Danel; A Foulet-Roge; A Gibbs; S Giusiano-Courcambeck; K Hiroshima; V Hofman; A N Husain; K Kerr; A Marchevsky; K Nabeshima; J M Picquenot; I Rouquette; C Sagan; J L Sauter; F Thivolet; W D Travis; M S Tsao; B Weynand; F Damiola; A Scherpereel; J C Pairon; S Lantuejoul; V Rusch; N Girard
Journal:  J Thorac Oncol       Date:  2018-04-30       Impact factor: 15.609

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.